Crossing the next frontier
to give you a fair chance to fight

Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation therapies in immuno-oncology and immuno-inflammation.

Our novel candidates harness microbiome-associated innate immune regulatory mechanisms to enhance patient's responsiveness to treatments
in indications where dysregulated immunity hampers efficacy, including inflammatory bowel diseases, solid tumor cancers and some infectious diseases.

Modulating the immune system...

EXL01 - Exeliom's lead drug candidate - is a first-in-class oral drug with a novel mechanism of action that demonstrates enhanced activation of key regulators of the innate immune system.

In immuno-inflammation, EXL01 facilitates resolution of inflammation in a non-suppressive manner by favoring a regulatory phenotype of antigen presenting cells, downregulating proinflammatory T cells and upregulating a specific Treg subpopulation.

In immuno-oncology, immune checkpoint inhibitors binding to their targets shift the intracellular signalling induced by EXL01 with upregulation of Th1 immunity and synergistic anti-tumour effects.

EXL01 harnesses the immuno-modulatory properties of the commensal bacterium Faecalibacterium prausnitzii.

... in conditions where dysregulated immunity hampers efficacy of existing treatments

EXL01 is being evaluated in several clinical trials, including a phase I trial in Crohn's disease, two phase II trials in immuno-oncology in combination with immune checkpoint inhibitors (Gastric cancer and Non-small cell lung cancer), and one phase I/II trial in the prevention of recurrent C. difficile infection.
Two additional Phase II studies evaluated EXL01 are planned to start in end of 2024: one in hepatocellular carcinoma in combination with an immune checkpoint inhibitor and one in postoperative Crohn's disease.

Overall, more than 300 patients across 6 indications will receive EXL01, generating an extensive dataset to demonstrate its therapeutic and commercial potential.

Giving patients a fair chance to fight is why we seek out unexplored therapeutic

solutions, and why we founded Exeliom Biosciences. 

About us

Exeliom is based on strong scientific foundations and has a world-renowned team, led by Pr. Harry Sokol, gastroenterologist and hepatologist at Saint-Antoine Hospital,AP-HP and Sorbonne University, Dr. Philippe Langella, research director at INRAE, and Pr. Patrick Gervais, process engineering specialist at AgroSup. 

Founded in 2016 and headquartered in Paris, Exeliom has raised a total of €24 million ($26M) since its inception.

The company has been awarded the ‘Deeptech’ and ‘I-Lab’ awards by Bpifrance, and the ‘EIC Accelerator’ by the European Innovation Council Fund. It has also received financial supportfrom the Crohn's & Colitis Foundation of America.

Giving patients a fair chance to fight is why we seek out unexplored therapeutic solutions, and why we founded Exeliom Biosciences. 


We intend to build our future through partnerships.
Reach out to us to start the discussion or follow us on Linkedin


our past


Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.